VHIO’s Scientific Management Area is a well-established Unit that supports our leadership and promotes the scientific activity of our research groups by facilitating the development and execution of scientific proposals and programs. In addition, we coordinate the activities of VHIO’s Task Forces to foster synergies between our multidisciplinary teams and spur joint research programs in oncology at the Vall d’Hebron University Hospital – HUVH (Vall d’Hebron Barcelona Hospital Campus).
Our responsibilities include financial and scientific management, strategic scientific support, and the implementation of institutional actions across transversal areas such as education, ethics and regulatory issues, scientific dissemination, and the coordination of research activities related to VHIO’s participation in several consortia and partnerships globally. Additional activities include the assessment and preparation of grant application proposals, dissemination of national and international funding opportunities for research groups, and the continued monitoring and coordination of awarded research projects, among others.
Our group further optimizes opportunities for the internationalization of researchers by devising personalized plans for VHIO's scientific groups, centralizes and conceptualizes research proposals from our Task Forces, and proactively matches selected research priorities with competitive calls. We also spearhead highly innovative technological project proposals to increase VHIO’s success rate in calls, such as the Innovative Medicines Initiative (IMI) within the Horizon Europe framework, and oversee VHIO’s involvement in European projects as project coordinators or partners. Lastly, our Area is continuously working to enhance its organizational structure and project management processes with the goal of expanding VHIO’s capacity to conduct research of excellence in oncology.
Identify and promote new research opportunities involving academic and industry partners.
Write, coordinate and manage scientific proposals.
Launch and monitor institutional research programs.
Promote intramural research through education, networking, and communication programs.
In 2021, we maintained a good track record with a success rate of 29%, out of 189 grant (competitive) applications.
Our Area has managed more than 9.5 million EUR granted through the proposals submitted in 2021 by VHIO groups.
Reflective of the research support that we provide to VHIO is our co-authorship of several publications (see Paper Pick).
We co-lead major EU consortia. Just some of these include the Cancer Core Europe (CCE) consortium’s CCE-DART project – the first H2020 grant awarded to the Cancer Core Europe Consortium, COLOSSUS (H2020), and CCE’s Basket of Baskets. We are also collaborate with numerous project boards and are in involved in several other work packages.
We have provided support to our Scientific Direction through the management of scientific data and all the necessary documentation and actions required to develop research proposals. Additionally, we have secured funding from the Spanish Ministry of Economic Affairs and Digital Transformation (MINECO), and obtained a European Networks and Management grant to support the internationalization of our research and dissemination activities and personnel.
Martinez-Marti A, Felip E, Mancuso FM, Caratú G, Matito J, Nuciforo P, Sansano I, Diaz-Mejia N, Cedrés S, Callejo A, Iranzo P, Pardo N, Miquel JM, Navarro A, Vivancos A, Sansó M. Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer. Br J Cancer. 2021 Nov;125(11):1561-1569.
Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Piris-Gimenez A, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA 2nd, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH; PDXNET Consortium; EurOPDX Consortium. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet. 2021 Jan;53(1):86-99.
ACADEMIC CRO (VHIO - aCRO)
VHIO's Academic Contract Research Organization (VHIO - aCRO), has extensive experience in conducting sponsored trials and investigator-initiated trials (IITs). We offer a complete package of start-to-end management services required to perform clinical trials and studies. Our multidisciplinary team enables us to operate as a full service CRO in clinical studies from phase I to IV.
We also provide guidance to all researchers and sponsors on how to achieve the best experimental design, and offer logistical advice in order to maximize their resources. With a team of 10 professionals, our Unit provides medical writing support, full regulatory activities, monitoring, project management, e-CRF creation, statistics, drug management, insurance management, and pharmacovigilance activities.
We seek to expand our Unit by incorporating a clinical project manager and a clinical trials assistant. This will allow us to even more effectively manage current and future clinical trials, optimize CRO digital tools for working remotely, as well as continue to bring out the best in each team member to enhance VHIO’s aCRO.
We seek to expand our Unit’s structure with a clinical project manager and a CRA to be able to even more effectively manage current and future clinical trials, optimize CRO digital tools to allow for working remotely, as well as continue to bring out the best in each team member to enhance our newly created Facility.
Clinical project management support to awarded R&D projects (European/Pharma funded), academic oncology clinical trials led by our Medical Oncologists and Clinical Investigators at VHIO and the Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Barcelona Hospital Campus.
Academic CRO for IITs.
Academic CRO for pharmacy sponsored trials where VHIO is involved in the development of the studies.
In 2021, our academic CRO successfully managed a number of major projects including AGI-134.FIM.101, TOPIC, IRONMAN, MONEO, DUREC, BRCA-P, CA209-7J3, MoTriColor, BoB, among others. Most of these are led by by our Medical Oncologists and Clinical Investigators at Vall d'Hebron's Medical Onology Department, headed by Josep Tabernero, VHIO’s Director.
Of particular note, two clinical trials in cell therapy with TILs and NKs initiated this year. These studies are logistically managed by our Unit.
During 2021, we successfully met the regulatory requirements for all our trials (first submissions and amendments).
Our CRA team monitored more than 150 patients in different hospitals across Spain.
We managed clinical trial drug requirements in more than 25 national hospitals.
We have also demonstrated sufficient benefits that support CRO activities for non-funded academic trials.